Dermavant Sciences Ltd Contracts & Agreements
40 Contracts & Agreements
- Business Finance (10 contracts)
- Business Operations (6)
- Human Resources (8)
- Intellectual Property (10)
- Real Estate (3)
- Uncategorized (3)
- Form of Underwriting Agreement (Filed With SEC on June 10, 2019)
- Registration Rights Agreement, dated as of June 7, 2019, by and between Roivant Sciences Ltd. and the Registrant (Filed With SEC on June 10, 2019)
- Amended and Restated Information Sharing and Cooperation Agreement, effective as of June 7, 2019, by and between Dermavant Sciences Ltd. and Roivant Sciences Ltd (Filed With SEC on June 10, 2019)
- 2016 Equity Incentive Plan, as amended and restated (Filed With SEC on June 10, 2019)
- Forms of Option Grant Notice and Option Agreement under the 2016 Equity Incentive Plan, as amended and restated (Filed With SEC on June 10, 2019)
- Form of Early Exercise Stock Purchase Agreement under 2016 Equity Incentive Plan, as amended and restated (Filed With SEC on June 10, 2019)
- Form of Indemnification Agreement with directors and executive officers (Filed With SEC on June 10, 2019)
- Loan and Security Agreement, dated as of May 24, 2019, by and between Dermavant Sciences Ltd., Dermavant Sciences, Inc., Dermavant Sciences GmbH and Dermavant Holdings Limited and... (Filed With SEC on June 10, 2019)
- Warrant Agreement, dated as of May 31, 2019, by and between Dermavant Sciences Ltd. and Hercules Capital, Inc (Filed With SEC on June 10, 2019)
- Intercreditor Agreement, dated as of May 24, 2019, by and between Hercules Capital, Inc., the Intra-Group Lenders (as defined in the agreement), the Intra-Group Debtors (as... (Filed With SEC on June 10, 2019)
- Asset Purchase Agreement, dated as of July 10, 2018, by and among Dermavant Sciences GmbH, GlaxoSmithKline Intellectual Property Development Ltd. and Glaxo Group Limited (Filed With SEC on May 24, 2019)
- License Agreement, dated November 19, 2015, by and between Dermavant Sciences GmbH and Eisai Co., Ltd (Filed With SEC on May 24, 2019)
- First Amendment, dated as of July 7, 2017, to the License Agreement, dated as of November 19, 2015, by and between Dermavant Sciences GmbH and Eisai Co., Ltd (Filed With SEC on May 24, 2019)
- License Agreement, dated as of December 16, 2016, by and between Dermavant Sciences GmbH and Portola Pharmaceuticals, Inc (Filed With SEC on May 24, 2019)
- First Amendment, dated as of July 7, 2017, to the License Agreement, dated as of December 16, 2016, by and between Dermavant Sciences GmbH and Portola Pharmaceuticals, Inc (Filed With SEC on May 24, 2019)
- License Agreement, dated as of September 19, 2017, by and between Roivant Sciences GmbH and AstraZeneca AB (Filed With SEC on May 24, 2019)
- License Agreement, dated as of January 31, 2018, by and between Roivant Sciences GmbH and TheraVida, Inc (Filed With SEC on May 24, 2019)
- China and South Korea IP Purchase Agreement, effective as of June 12, 2017, by and between Dermavant Sciences GmbH and Roivant Sciences GmbH (Filed With SEC on May 24, 2019)
- Assignment and Assumption Agreement, dated as of December 17, 2018, by and between Dermavant Sciences GmbH and Roivant Sciences GmbH, relating to the License Agreement by and... (Filed With SEC on May 24, 2019)
- Sublicense Agreement, dated as of December 17, 2018, by and between Dermavant Sciences GmbH and Roivant Sciences GmbH, relating to the License Agreement by and between Roivant... (Filed With SEC on May 24, 2019)
- Assignment and Assumption Agreement, dated as of December 17, 2018, by and between Dermavant Sciences GmbH and Roivant Sciences GmbH, relating to the License Agreement by and... (Filed With SEC on May 24, 2019)
- Sublicense Agreement, dated as of December 17, 2018, by and between Dermavant Sciences GmbH and Roivant Sciences GmbH, relating to the License Agreement by and between Roivant... (Filed With SEC on May 24, 2019)
- Amended and Restated Roivant Commitment Letter, dated as of April 12, 2019, by and between Dermavant Sciences GmbH, Roivant Sciences Ltd. and the Registrant (Filed With SEC on May 24, 2019)
- Funding Agreement, dated as of July 10, 2018, by and between Dermavant Sciences GmbH and NovaQuest Co-Investment Fund VIII, L.P (Filed With SEC on May 24, 2019)
- First Amendment, effective as of October 11, 2018, to the Funding Agreement, dated as of July 10, 2018, by and between Dermavant Sciences GmbH and NovaQuest Co-Investment Fund... (Filed With SEC on May 24, 2019)
- Capital Expenditure Letter Agreement, dated November 5, 2018, by and between Dermavant Sciences GmbH and GlaxoSmithKline (Filed With SEC on May 24, 2019)
- Amended and Restated Services Agreement, effective as of August 20, 2018, by and between Roivant Sciences, Inc., Dermavant Sciences GmbH, Dermavant Sciences, Inc. and the... (Filed With SEC on May 24, 2019)
- Amended and Restated Services Agreement, effective as of August 20, 2018, by and between Roivant Sciences GmbH and Dermavant Sciences GmbH (Filed With SEC on May 24, 2019)
- Employment Agreement, dated March 18, 2019, by and between Cyril Allouche and Dermavant Sciences, Inc (Filed With SEC on May 24, 2019)
- Employment Agreement, dated March 22, 2018, by and between Christopher Van Tuyl and Dermavant Sciences, Inc (Filed With SEC on May 24, 2019)
- Separation Agreement and General Release, dated September 4, 2018, by and between Jacqualyn Fouse, Ph.D. and Dermavant Sciences, Inc (Filed With SEC on May 24, 2019)
- Office Lease Agreement, dated as of March 19, 2018, between Biltmore Center II, AB/VWP BFC Owner, LLC, and Dermavant Sciences, Inc (Filed With SEC on May 24, 2019)
- First Amendment, dated as of June 29, 2018, to the Office Lease Agreement, dated March 19, 2018, between Biltmore Center II, AB/VWP BFC Owner, LLC, and Dermavant Sciences, Inc (Filed With SEC on May 24, 2019)
- Employment Agreement, dated October 27, 2018, by and between Todd Zavodnick and Dermavant Sciences, Inc (Filed With SEC on May 24, 2019)
- Employment Agreement, dated December 6, 2018, by and between Philip Brown, M.D. and Dermavant Sciences, Inc (Filed With SEC on May 24, 2019)
- Option Agreement, effective as of March 28, 2019, by and between Dermavant Sciences GmbH and Roivant Sciences GmbH (Filed With SEC on May 24, 2019)
- Clinical Supply and Manufacturing Agreement, dated August 20, 2018, by and between Dermavant Sciences GmbH and GlaxoSmithKline (Filed With SEC on May 24, 2019)
- Commercial Supply and Manufacturing Agreement, dated April 1, 2019, by and between Dermavant Sciences GmbH and GlaxoSmithKline (Filed With SEC on May 24, 2019)
- Asset Purchase Agreement, dated May 29, 2012, by and between Glaxo Group Limited and Welichem Biotech Inc., as amended (Filed With SEC on May 24, 2019)
- Office Lease Agreement, dated as of March 15, 2019, between Kilroy Realty, L.P. and Dermavant Sciences Inc (Filed With SEC on May 24, 2019)
